Currently, anti-obesity medications confront various challenges, such as heterogeneity of patient cohorts and safety, and the novel drug candidates on basis of several promising therapeutic targets (leptin, incretin, ghrelin, mitochondrial uncoupler, and growth differentiation factor 15) have been advanced to human trials (12). The gene discussed is GHRL; the disease is Obesity.